Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

With 13 states offering coverage, it’s already a $3.9 billion cost. Some state officials say reducing obesity will save programs money in the long run.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

Direct-to-consumer healthcare startup Ro announced Wednesday that its platform will now offer cheaper single-dose vials of the weight loss drug Zepbound through a new partnership with Eli Lillywhich ...

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

FDA has ordered specialty pharmacies and online companies to phase out knockoff versions of Eli Lilly blockbuster drugs ...

FDA has ordered specialty pharmacies and online companies to phase out knockoff versions of Eli Lilly's blockbuster drugs ...

With demand for these drugs skyrocketing, telehealth and compounding pharmacies like Hims and Ro began to offer off-brand and cheaper versions of Zepbound and Mounjaro. According to the press ...

The FDA has announced that popular weight loss medication tirzepatide is no longer in shortage, potentially removing cheaper versions of the drug from the market by early 2025. Tirzepatide is the ...

Shelby Knowles / Bloomberg / Getty Images Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with sleep apnea and obesity, the drugmaker ...